Issue of Equity and PDMR sharedealing InPublic Issue of Equity and PDMR sharedealing

DXS INTERNATIONAL PLC

Issue of Equity and Director Dealing

The Board of DXS International plc (the “Company”), the NEX quoted clinical decision support developer and supplier of clinical decision support systems is pleased to confirm that on 5 April 2019 it received subscriptions for the issue of a total of 400,000 new Ordinary Shares of 0.33p each at a price of 10p each. The monies were subscribed by long standing existing shareholders. John Godley will, after this subscription, hold 1,496,667 Ordinary Shares representing 4.21% of the total ordinary shares in issue.

Following this transaction, the issued share capital of the Company is now 35,581,416 ordinary shares. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

The Company has also been notified that the Chief Executive, David Immelman, has purchased 4,282 Ordinary Shares on 4 April at a price of 11.5p per share. Following the transaction specified above Mr Immelman holds 3,701,673 Ordinary Shares representing 10.40% of the issued share capital of the Company.

The Directors of DXS International plc accept responsibility for this announcement

Enquiries:

David Immelman   (Chief Executive)
DXS International plc
01252 719800
david@dxs-systems.com
Wrecclesham House
Wrecclesham Road
Farnham
Surrey
GU10 4PS
 
www.dxs-systems.co.uk 


David Papworth
City & Merchant
0207 101 7676
info@cityandmerchant.com
Level 17, Dashwood House
69 Old Broad Street,
London
EC2M 1QS
 

Note to Editors:

DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively which should significantly contribute towards the NHS achieving its projected efficiency savings.

]]>